Schrödinger Announces Acquisition of XTAL BioStructures, Inc.

NEW YORK--(BUSINESS WIRE)--Jan. 18, 2022-- Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced the acquisition of XTAL BioStructures, Inc., a private company based in the Greater Boston area that provides structural biology services, including biophysical methods, protein production and purification, and X-ray crystallography, to the pharmaceutical and biotechnology industries. More>>

Treadwell Therapeutics Engages Genezen to Advance its T Cell Receptor-Based Cell Therapy Pipeline

Treadwell Therapeutics, a clinical stage, multi-modality biotechnology company developing novel therapeutics for highly aggressive cancers, and Genezen, a cell and gene therapy Contract Development and Manufacturing Organisation (CDMO) have confirmed a partnership agreement to accelerate the production of T cell receptor (TCR)-based candidates to address unmet needs in cancer patients. More>>

PhoreMost expands into new facility at Unity Campus, Cambridge, UK

Cambridge, UK, 18 January 2022: PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets, today announced it has relocated its headquarters to Unity Campus, a high-specification technology and innovation park, owned by leading regional property developers and investors, Howard Group, in south Cambridge. More>>

ACG introduces Smart Connected Product to enable remote machine monitoring in real-time

Mumbai 12th January, 2022 - New solution improves machine efficiency, prevents breakdowns, lowers costs and reduces risks whilst providing anytime, anywhere remote monitoring. ACG, the world’s leading integrated solutions provider for pharmaceutical companies, has introduced the Smart Connected Product - a new, innovative, IIoT solution, that connects production machines at any facility and visualises relevant information on a single platform. This data can be viewed over the web on any device with a secure connection and is accessible only to authorised users. More>>

Analytical Service Leaders in Biopharmaceutical and Gene Therapy Development Unify Operations and Re-brand as ProtaGene

Heilbronn & Heidelberg, Germany and Boston, USA – January 12, 2022: Following the announced merger in July 2021, Protagen Protein Services GmbH, BioAnalytix, Inc., and GeneWerk GmbH today announced their unified operations and re-brand as ProtaGene, a world-leading CRO partner for the biopharmaceutical and cell & gene therapy industries. More>>

Fresenius Kabi modernises production facility in France

Fresenius Kabi is investing about €35 million to modernise the company’s production facility in Louviers, France. Two sterilisation units and two production lines for Freeflex® infusion bags will be housed in a 3,300-square-meter (35,500-square-foot) building being constructed on the site and will replace the existing production facilities. In this way, the company will continue to ensure the availability of these important products into the future. The modernisation is scheduled for completion before the end of 2023. Fresenius Kabi employs some 370 people at the Louviers plant and has a total of about 1,500 employees in France. More>>

Exscientia and Sanofi Establish Strategic Research Collaboration to Develop AI-driven Pipeline of Precision-Engineered Medicines

PARIS & OXFORD, England & BOSTON--(BUSINESS WIRE)-- Sanofi and Exscientia announced today a groundbreaking research collaboration and license agreement to develop up to 15 novel small molecule candidates across oncology and immunology, leveraging Exscientia’s end-to-end AI-driven platform utilising actual patient samples. The companies have been working together since 2016 and in 2019, Sanofi in-licensed Exscientia’s novel bispecific small molecule candidate capable of targeting two distinct targets in inflammation and immunology. More>>

Ardena expands capacity to satisfy Novavax COVID vaccine demand

Gent, Belgium/December 2021: Ardena, a specialist pharmaceutical contract development and manufacturing organisation (CDMO), announced it will be expanding its capacity for purification and fractionation of GMP manufacturing at its site in Södertälje, Sweden. The expansion will satisfy long-term demand expected from Novavax for production of the company’s COVID-19 vaccine, among others. More>>

Thermo Fisher Scientific Completes Acquisition of PeproTech, a Leader in Recombinant Proteins

WALTHAM, Mass., Jan. 5, 2022 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, and PeproTech, Inc., a leading developer and manufacturer of recombinant proteins, today announced that Thermo Fisher completed its acquisition of PeproTech on December 30, 2021 for a total cash purchase price of approximately $1.85 billion. More>>

Altasciences Acquires Sinclair Research and Continues to Expand Preclinical Platform

Laval, Quebec, January 4, 2022 – Altasciences, an integrated CRO/CDMO offering pharmaceutical and biotechnology companies a seamless solution to early-stage drug development from lead candidate selection to clinical proof of concept, announced today the completed acquisition of Sinclair Research, a preclinical CRO located in the Midwest. Complementing existing locations on the East and West Coast, the new site will facilitate even greater access to Altasciences’ preclinical services across the US. More>>